%PDF-1.4
%
1 0 obj
<>stream
iText 4.2.0 by 1T3XT2020-01-03T15:52:53+05:30Arbortext Advanced Print Publisher2020-03-11T04:09:34-07:002020-03-11T04:09:34-07:00uuid:8addd02c-2a8d-4824-a074-0375b52bef83uuid:9735c38c-787b-4f5b-aca7-e8422204bc96JournalJournal of Dermatological Treatment© 2020 Taylor & Francis Group, LLC0954-66341471-1753001-51510.1080/09546634.2019.1708242https://doi.org/10.1080/09546634.2019.1708242application/pdf10.1080/09546634.2019.1708242en-USRetrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug AdministrationTaylor & FrancisJournal of Dermatological Treatment, 2020. doi: 10.1080/09546634.2019.1708242Wang YuLipner Shari R.Onychomycosisfungal nail infectionFDAFAERSadverse eventsliver toxicityterbinafinefluconazoleitraconazoletaste disturbanceASTALTdrug interactionGoogleGoogle TrendsVoR2020-01-06truewww.tandfonline.com10.1080/09546634.2019.1708242www.tandfonline.comtrue2020-01-0610.1080/09546634.2019.1708242
endstream
endobj
4 0 obj
<>stream
xYKo7"Q=z\zzjH/%)R̎$Űу#%